Healing Hearts and Mending Minds in Older Adults Living With HIV
NCT02711878, Not applicable, Completed, Emory University; results first posted 2022-07-01
Trial 11
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Healing Hearts and Mending Minds in Older Adults Living With HIV | ClinicalTrials.gov |
| NCT number | NCT02711878 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 115 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Emory University | ClinicalTrials.gov |
| Conditions | HIV, Cardiovascular Disease, AIDS | ClinicalTrials.gov |
| Interventions | Let's Move Program, Let's Flex Program, Group Motivational Interviewing | ClinicalTrials.gov |
| First posted | 2016-03-17 | ClinicalTrials.gov |
| Last updated | 2023-07-06 | ClinicalTrials.gov |
| Results first posted | 2022-07-01 | ClinicalTrials.gov |
Registered outcomes 23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Stroop Color and Word Test Score | Baseline, T1 (13-15 weeks post baseline), T2 (28-30 weeks post baseline), T3 ( 56-58 weeks post baseline) | The Stroop Color and Word Test is a performance-based test of executive function and inhibitory responding. The participant is presented with a page with the words "red, blue, and green" printed 100 times in (20 words in 5 columns). Each word is printed in a different color of ink than the target word (e.g, the word "red" is printed in blue ink). Participants read the color of ink in which the word is printed as quickly are possible within a time limit. The correct number within the time limit is the score. Raw scores (unadjusted for age and education) range from 0-100. | ClinicalTrials.gov |
| Primary | Trail Making Test Score | Baseline, T1 (13-15 weeks post baseline), T2 (28-30 weeks post baseline), T3 ( 56-58 weeks post baseline) | The Trail Making Test is a performance based test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect circles as possible while still maintaining accuracy. Trails A subtest requires the connection in sequence of 25 circles labeled by numbers. Trails B requires the connection in sequence of 25 circles labeled by alternating numbers and letters (1-A-2-B-3-C). The score on the test is the time in seconds that it takes to complete. Higher scores (i.e., time) indicate poorer performance. | ClinicalTrials.gov |
| Primary | Letter Fluency Assessed by Change in FAS Test Score | Baseline, T1 (13-15 weeks post baseline), T2 (28-30 weeks post baseline), T3 ( 56-58 weeks post baseline) | The FAS test requires stating out loud as many words that begin with the assigned letter (F, A, and S) as possible within 60-seconds. Results represent total number of words stated for F,A \& S combined. | ClinicalTrials.gov |
| Primary | Category Fluency Test Score | Baseline, T1 (13-15 weeks post baseline), T2 (28-30 weeks post baseline), T3 ( 56-58 weeks post baseline) | The category fluency test requires participants to state out load the names of as many animals as possible within 60-seconds. Results are total number of animals named. | ClinicalTrials.gov |
| Primary | Hopkins Verbal Learning Test (HVLT) - Revised Score | Baseline, T1 (13-15 weeks post baseline), T2 (28-30 weeks post baseline), T3 ( 56-58 weeks post baseline) | The HVLT-Revised is a list learning task requiring the respondent to recall as many words as possible from a list of 12 words provided orally by the examiner. There is a learning trial, a delayed recall trial, and a recognition trial. Results show HVLT Total recall (Total number if words recalled over 3 trials) and HVLT Delayed recall (Total number of words recalled after 25 minute delay). | ClinicalTrials.gov |
| Primary | Brief Visual Memory Test - Revised (BVMT-R) Score | Baseline, T1 (13-15 weeks post baseline), T2 (28-30 weeks post baseline), T3 ( 56-58 weeks post baseline) | The Brief Visual Memory Test is a performance based test that requires that participants reproduce simple visual images from memory (the images are displayed for 10 seconds then removed from view). The BVMT-R contains a learning trial, a recall trial, a recognition trial, and a copy trial. Each figure recalled is given 0,1, or 2 points based on accuracy and location recall. Results show BVMT Total recall (Total number if figures recalled over 3 trials: range 0 - 36) and BVMT delayed recall (total number of figures recalled after 25 min delay. Score range 0-12). Higher score correlate with better outcome. | ClinicalTrials.gov |
| Primary | Grooved Pegboard Test Score | Baseline, T1 (13-15 weeks post baseline), T2 (28-30 weeks post baseline), T3 ( 56-58 weeks post baseline) | The Grooved Pegboard Test requires the placing of grooved pegs into a same-shaped hole as quickly as possible, once with the dominant hand and once with the non-dominant hand. | ClinicalTrials.gov |
| Primary | Finger Tapping Test Score | Baseline, T1 (13-15 weeks post baseline), T2 (28-30 weeks post baseline), T3 ( 56-58 weeks post baseline) | The finger tapping test a fine motor speed requires tapping a lever with the index finger as quickly as possible. Trials with the dominant and non-dominant hand are completed. | ClinicalTrials.gov |
| Primary | Coding Test Score | Baseline, T1 (13-15 weeks post baseline), T2 (28-30 weeks post baseline), T3 ( 56-58 weeks post baseline) | The coding test requires writing the corresponding symbol associated with a letter from a key provided. As many responses as possible are completed in the 120 second time limit. Results presented are the total number of correct responses (possible score range 0-135). | ClinicalTrials.gov |
| Primary | Digit Span Test Score | Baseline, T1 (13-15 weeks post baseline), T2 (28-30 weeks post baseline), T3 ( 56-58 weeks post baseline) | The digit span test is a performance based test that requires repeating an increasing span of digits that are provided verbally by the examiner. The test includes trials of repeating digits in the same order presented by the examiner, in the reverse order of that presented by the examiner, and in ascending sequence. Scores range from 0 to 48. Higher score correlates with better outcome. | ClinicalTrials.gov |
| Primary | Symbol Span Test Score | Baseline, 3 months, 6 months and 12 months Post Intervention | The subtest assesses visual working memory using novel visual stimuli. A series of abstract symbols on a page are shown briefly. Then the symbols are to be selected from an array of symbols in the same order they were presented on the previous page. This performance based test measures storage and manipulation of visual details in working memory. Score range from 0-36. Higher score correlates with better outcome. | ClinicalTrials.gov |
| Primary | Instrumental Activities of Daily Living (IADL) Test Score | Baseline, T1 (13-15 weeks post baseline), T2 (28-30 weeks post baseline), T3 (56-58 weeks post baseline) | The Instrumental Activities of Daily Living (IADL) Test is a self-report measure assessing the amount of assistance, if any, required to do day-to-day tasks necessary to live independently. A summary score ranges from 0 (low function, dependent) to 8 (high function, independent) for women and 0 through 5 for men to avoid potential gender bias). Higher scores indicate worse performance in instrumental activities activities of daily living. | ClinicalTrials.gov |
| Primary | NIH Toolbox | Baseline, Post Intervention (Up to 58 weeks) | Computerized cognitive tests developed and distributed by the NIH. Tests include Pattern Comparison Processing Speed Test, Picture Vocabulary Test, Reading Recognition Test, Dimensional Change Card Sort Test, Flanker Inhibitory Control and Attention Test, Picture Sequence Memory Test, List Sorting Working Memory Test, and Oral Symbol Digit Test | ClinicalTrials.gov |
| Secondary | Soluble Cluster of Differentiation 14 (sCD14) Level | Baseline, T1 (13-15 weeks), T2 (28-30 weeks), T3 (56 -58 weeks) | Soluble Cluster of Differentiation 14 (sCD14) is a marker of monocyte activation, is associated with neurocognitive impairment and HIV-associated neurocognitive disorders (HANDs) and higher mortality in persons living with HIV. | ClinicalTrials.gov |
| Secondary | Interleukin 6 (IL-6) Level | Baseline, T1 (13-15 Weeks), T2 (28-30 weeks), T3 (56-58 weeks) | IL-6 is a pro-inflammatory cytokine known to contribute to the pathogenesis of risk of cardiovascular disease (CVD) and cognitive impairment (CI) through inflammation and promotion of endothelial vascular dysfunction. IL-6 is measured by enzyme-linked immunosorbent assay (ELISA) and reported as in picograms per deciliter (pg/dL). Higher concentrations of IL-6 raise congenital heart defect risk. | ClinicalTrials.gov |
| Secondary | Tumor Necrosis Factor Alpha (TNF-alpha) Level | Baseline, T1 (13-15 wks), T2 (28-30 wks), T3 (56-58 wks) | TNFR1 membrane bound receptors that have been shown to bind TNF alpha. Activation of TNFR1 mediates the proinflammatory properties of TNF alpha. | ClinicalTrials.gov |
| Secondary | Brain-derived Neurotrophic Factor (BDNF) Level | Baseline, Post Intervention (Up to 58 weeks) | BDNF is a protein that occurs naturally in the hippocampus, cortex, and basal forebrain-areas vital to learning, memory, and higher thinking; an increase in BDNF in animal models and humans is thought to enhance neurogenesis. BDNF is reported as in picogram per milliliter (pg/mL). | ClinicalTrials.gov |
| Secondary | Flow-Mediated Dilatation (FMD) | Baseline, T2 (28-30 weeks post baseline) | Flow-mediated dilatation (FMD) is a measure of endothelial function; the measure of % FMD at 60 seconds reflects arterial relaxation time after cuff deflation. | ClinicalTrials.gov |
| Other | Pittsburgh Sleep Quality Index (PSQI) Score | Baseline, T2 (28-30 weeks post baseline), T3 (56-58 weeks post baseline) | The Pittsburgh Sleep Quality Index (PSQI) is a 19-item measure of the quality and patterns of sleep among adults. Scoring is based on a 0 to 3 Likert scale. The global score is 21; total possible score ranges from 0 to 21. The higher the score the worse the sleep quality. | ClinicalTrials.gov |
| Other | Beck Depression Inventory-II (BDI-II) Score | Baseline, T2 (28-30 weeks post baseline), T3 (56-58 weeks post baseline) | BDI-II is a 21-question multiple-choice self-report inventory, one of the most widely used instruments for measuring the severity of depression. Each answer being scored on a scale value of 0 to 3. Scores range from 0-63. Interpretation: 0 through 9 indicate no or minimal depression; scores from 10 through 18 indicate mild to moderate depression; scores from 19 through 29 indicate moderate to severe depression; and scores from 30 through 63 indicate severe depression. | ClinicalTrials.gov |
Outcomes 23
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|---|---|---|---|---|---|
| PRIMARY | Stroop Color and Word Test Score | Baseline, T1 (13-15 weeks post baseline), T2 (28-30 weeks post baseline), T3 ( 56-58 weeks post baseline) | The number analyzed includes participants who were able to complete each study visit. | number of correct responses | MEAN | ClinicalTrials.gov |
| PRIMARY | Trail Making Test Score | Baseline, T1 (13-15 weeks post baseline), T2 (28-30 weeks post baseline), T3 ( 56-58 weeks post baseline) | The number analyzed includes participants who were able to complete each study visit. | seconds | MEAN | ClinicalTrials.gov |
| PRIMARY | Letter Fluency Assessed by Change in FAS Test Score | Baseline, T1 (13-15 weeks post baseline), T2 (28-30 weeks post baseline), T3 ( 56-58 weeks post baseline) | The number analyzed includes participants who were able to complete each study visit. | number of correct words | MEAN | ClinicalTrials.gov |
| PRIMARY | Category Fluency Test Score | Baseline, T1 (13-15 weeks post baseline), T2 (28-30 weeks post baseline), T3 ( 56-58 weeks post baseline) | Some participants did not complete the form or completed the incorrect forms and could not be included in the analysis. | Number of correct animals named | MEAN | ClinicalTrials.gov |
| PRIMARY | Hopkins Verbal Learning Test (HVLT) - Revised Score | Baseline, T1 (13-15 weeks post baseline), T2 (28-30 weeks post baseline), T3 ( 56-58 weeks post baseline) | Some participants did not complete the form or completed the incorrect forms and could not be included in the analysis. | Number of correct words recalled | MEAN | ClinicalTrials.gov |
| PRIMARY | Brief Visual Memory Test - Revised (BVMT-R) Score | Baseline, T1 (13-15 weeks post baseline), T2 (28-30 weeks post baseline), T3 ( 56-58 weeks post baseline) | Some participants did not complete the form or completed the incorrect forms and could not be included in the analysis. | number of correct figures recalled | MEAN | ClinicalTrials.gov |
| PRIMARY | Grooved Pegboard Test Score | Baseline, T1 (13-15 weeks post baseline), T2 (28-30 weeks post baseline), T3 ( 56-58 weeks post baseline) | The number analyzed includes participants who were able to complete each study visit. | Seconds | MEAN | ClinicalTrials.gov |
| PRIMARY | Finger Tapping Test Score | Baseline, T1 (13-15 weeks post baseline), T2 (28-30 weeks post baseline), T3 ( 56-58 weeks post baseline) | The number analyzed includes participants who were able to complete each study visit. | Seconds | MEAN | ClinicalTrials.gov |
| PRIMARY | Coding Test Score | Baseline, T1 (13-15 weeks post baseline), T2 (28-30 weeks post baseline), T3 ( 56-58 weeks post baseline) | The number analyzed includes participants who were able to complete each study visit. | number of correct responses | MEAN | ClinicalTrials.gov |
| PRIMARY | Digit Span Test Score | Baseline, T1 (13-15 weeks post baseline), T2 (28-30 weeks post baseline), T3 ( 56-58 weeks post baseline) | The number analyzed includes participants who were able to complete each study visit. | number of correct digits | MEAN | ClinicalTrials.gov |
| PRIMARY | Symbol Span Test Score | Baseline, 3 months, 6 months and 12 months Post Intervention | The number analyzed includes participants who were able to complete each study visit. | score on a scale | MEAN | ClinicalTrials.gov |
| PRIMARY | Instrumental Activities of Daily Living (IADL) Test Score | Baseline, T1 (13-15 weeks post baseline), T2 (28-30 weeks post baseline), T3 (56-58 weeks post baseline) | The number analyzed includes participants who were able to complete each study visit. | Score on a scale | MEAN | ClinicalTrials.gov |
| PRIMARY | NIH Toolbox | Baseline, Post Intervention (Up to 58 weeks) | In order to reduce participant burden, the NIH toolbox neurocognitive tests were not administered because was redundant with the outcomes measured by the other cognitive tests. | ClinicalTrials.gov | ||
| SECONDARY | Soluble Cluster of Differentiation 14 (sCD14) Level | Baseline, T1 (13-15 weeks), T2 (28-30 weeks), T3 (56 -58 weeks) | Lab assays were completed at each time-point based on the participants availability and those samples that were good for lab processing. | pg/ml | MEAN | ClinicalTrials.gov |
| SECONDARY | Interleukin 6 (IL-6) Level | Baseline, T1 (13-15 Weeks), T2 (28-30 weeks), T3 (56-58 weeks) | Lab assays were completed at each time-point based on the participants availability and those samples that were good for lab processing. | pg/ml | MEAN | ClinicalTrials.gov |
| SECONDARY | Tumor Necrosis Factor Alpha (TNF-alpha) Level | Baseline, T1 (13-15 wks), T2 (28-30 wks), T3 (56-58 wks) | Lab assays were completed at each time-point based on the participants availability and those samples that were good for lab processing. | pg/ml | MEAN | ClinicalTrials.gov |
| SECONDARY | Brain-derived Neurotrophic Factor (BDNF) Level | Baseline, Post Intervention (Up to 58 weeks) | pg/mL | MEAN | ClinicalTrials.gov | |
| SECONDARY | Flow-Mediated Dilatation (FMD) | Baseline, T2 (28-30 weeks post baseline) | The number analyzed includes participants who were able to complete each study visit. | percent dilation | MEAN | ClinicalTrials.gov |
| OTHER_PRE_SPECIFIED | Pittsburgh Sleep Quality Index (PSQI) Score | Baseline, T2 (28-30 weeks post baseline), T3 (56-58 weeks post baseline) | The number analyzed includes participants who were able to complete each study visit. | score on a scale | MEAN | ClinicalTrials.gov |
| OTHER_PRE_SPECIFIED | Beck Depression Inventory-II (BDI-II) Score | Baseline, T2 (28-30 weeks post baseline), T3 (56-58 weeks post baseline) | The number analyzed includes participants who were able to complete each study visit. | score on a scale | MEAN | ClinicalTrials.gov |
Results by group 194
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|---|---|---|---|---|---|
| Stroop Color and Word Test Score | Let's Move Program | Baseline | 31.17 | Standard Deviation 8.13 | number of correct responses | ClinicalTrials.gov |
| Stroop Color and Word Test Score | Let's Flex Program | Baseline | 28.89 | Standard Deviation 7.59 | number of correct responses | ClinicalTrials.gov |
| Stroop Color and Word Test Score | Let's Move Program | T1 (13-15 weeks post baseline) | 32.87 | Standard Deviation 8.85 | number of correct responses | ClinicalTrials.gov |
| Stroop Color and Word Test Score | Let's Flex Program | T1 (13-15 weeks post baseline) | 30.69 | Standard Deviation 6.64 | number of correct responses | ClinicalTrials.gov |
| Stroop Color and Word Test Score | Let's Move Program | T2 (28-30 weeks post baseline) | 33.09 | Standard Deviation 8.72 | number of correct responses | ClinicalTrials.gov |
| Stroop Color and Word Test Score | Let's Flex Program | T2 (28-30 weeks post baseline) | 30.39 | Standard Deviation 9.5 | number of correct responses | ClinicalTrials.gov |
| Stroop Color and Word Test Score | Let's Move Program | T3 ( 56-58 weeks post baseline) | 33.44 | Standard Deviation 8.74 | number of correct responses | ClinicalTrials.gov |
| Stroop Color and Word Test Score | Let's Flex Program | T3 ( 56-58 weeks post baseline) | 31.77 | Standard Deviation 7.83 | number of correct responses | ClinicalTrials.gov |
| Trail Making Test Score | Let's Move Program | Part A - Baseline | 35.84 | Standard Deviation 14.11 | seconds | ClinicalTrials.gov |
| Trail Making Test Score | Let's Flex Program | Part A - Baseline | 37.74 | Standard Deviation 20.08 | seconds | ClinicalTrials.gov |
| Trail Making Test Score | Let's Move Program | Part A -T1 (13-15 weeks post baseline) | 33.62 | Standard Deviation 12.39 | seconds | ClinicalTrials.gov |
| Trail Making Test Score | Let's Flex Program | Part A -T1 (13-15 weeks post baseline) | 35.58 | Standard Deviation 16.51 | seconds | ClinicalTrials.gov |
| Trail Making Test Score | Let's Move Program | Part A - T2 (28-30 weeks post baseline) | 34.73 | Standard Deviation 17.54 | seconds | ClinicalTrials.gov |
| Trail Making Test Score | Let's Flex Program | Part A - T2 (28-30 weeks post baseline) | 39.03 | Standard Deviation 15.62 | seconds | ClinicalTrials.gov |
| Trail Making Test Score | Let's Move Program | Part A - T3 ( 56-58 weeks post baseline) | 33.29 | Standard Deviation 12.49 | seconds | ClinicalTrials.gov |
| Trail Making Test Score | Let's Flex Program | Part A - T3 ( 56-58 weeks post baseline) | 36.23 | Standard Deviation 12.92 | seconds | ClinicalTrials.gov |
| Trail Making Test Score | Let's Move Program | Part B - Baseline | 113.7 | Standard Deviation 62.29 | seconds | ClinicalTrials.gov |
| Trail Making Test Score | Let's Flex Program | Part B - Baseline | 137.95 | Standard Deviation 86.58 | seconds | ClinicalTrials.gov |
| Trail Making Test Score | Let's Move Program | Part B -T1 (13-15 weeks post baseline) | 109.51 | Standard Deviation 58.68 | seconds | ClinicalTrials.gov |
| Trail Making Test Score | Let's Flex Program | Part B -T1 (13-15 weeks post baseline) | 142.26 | Standard Deviation 93.74 | seconds | ClinicalTrials.gov |
Participant flow 12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|---|---|---|---|---|
| Overall Study | STARTED | Let's Move Program | 76 | ClinicalTrials.gov | |
| Overall Study | STARTED | Let's Flex Program | 39 | ClinicalTrials.gov | |
| Overall Study | Completed Visit T1 (13-15 Weeks Post Baseline) | Let's Move Program | 69 | ClinicalTrials.gov | |
| Overall Study | Completed Visit T1 (13-15 Weeks Post Baseline) | Let's Flex Program | 33 | ClinicalTrials.gov | |
| Overall Study | Completed Visit T2 (28-30 Weeks Post Baseline) | Let's Move Program | 68 | ClinicalTrials.gov | |
| Overall Study | Completed Visit T2 (28-30 Weeks Post Baseline) | Let's Flex Program | 33 | ClinicalTrials.gov | |
| Overall Study | Completed Visit T3 (56-58 Weeks Post Baseline) | Let's Move Program | 72 | ClinicalTrials.gov | |
| Overall Study | Completed Visit T3 (56-58 Weeks Post Baseline) | Let's Flex Program | 31 | ClinicalTrials.gov | |
| Overall Study | COMPLETED | Let's Move Program | 68 | ClinicalTrials.gov | |
| Overall Study | COMPLETED | Let's Flex Program | 33 | ClinicalTrials.gov | |
| Overall Study | NOT COMPLETED | Let's Move Program | 8 | ClinicalTrials.gov | |
| Overall Study | NOT COMPLETED | Let's Flex Program | 6 | ClinicalTrials.gov |
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 6
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|---|---|---|---|
| Total, all-cause mortality | Let's Move Program | 0 | 76 | ClinicalTrials.gov |
| Total, all-cause mortality | Let's Flex Program | 0 | 39 | ClinicalTrials.gov |
| Total, other adverse events | Let's Move Program | 0 | 76 | ClinicalTrials.gov |
| Total, other adverse events | Let's Flex Program | 0 | 39 | ClinicalTrials.gov |
| Total, serious adverse events | Let's Move Program | 0 | 76 | ClinicalTrials.gov |
| Total, serious adverse events | Let's Flex Program | 0 | 39 | ClinicalTrials.gov |
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| R01NR014973 | Healing Hearts, Mending Minds in Older Persons with HIV | WALDROP, DRENNA; GARY, REBECCA A | EMORY UNIVERSITY | NATIONAL INSTITUTE OF NURSING RESEARCH | 2015 to 2018 | NIH RePORTER |
Trial comparisons 2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Let's Move Program vs Let's Flex Program: deaths from any cause | Trial comparisons |
| Let's Move Program vs Let's Flex Program: serious adverse events | Trial comparisons |
Tests 15
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Category Fluency | Primary outcome | ConductCognition |
| Digit Span Test | Primary outcome | ConductCognition |
| Dimensional Change Card Sort | Primary outcome | ConductCognition |
| Finger Tapping Task | Primary outcome | ConductCognition |
| Pattern and Letter Comparison | Primary outcome | ConductCognition |
| Picture Order Memory Test | Primary outcome | ConductCognition |
| Size Order Memory Test | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Symbol Coding | Primary outcome | ConductCognition |
| Task Switching Test | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
| Verbal Fluency | Primary outcome | ConductCognition |
| Verbal Learning | Primary outcome | ConductCognition |
| Vocabulary Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)